{ "dataset": { "name": "GLP-1 & Obesity Drug Pipeline", "url": "https://nphla.com/trackers/glp1-obesity-pipeline", "description": "Phase 2 and phase 3 clinical trials of GLP-1, amylin and other incretin-based obesity and metabolic medicines registered on ClinicalTrials.gov, with each study’s phase, recruitment status, sponsor and latest registry update.", "publisher": "National Pharmacy Health & Leadership Alliance", "howToCite": "National Pharmacy Health & Leadership Alliance (NPHLA). nphla.com. “GLP-1 & Obesity Drug Pipeline.” Updated Nov 15, 2026. https://nphla.com/trackers/glp1-obesity-pipeline. Accessed November 15, 2026.", "kind": "GLP-1 & obesity drug pipeline (ClinicalTrials.gov)", "dataOrigin": "NPHLA analysis of public data", "jurisdiction": "International / multiple", "methodology": "The Intelligence pipeline queries the ClinicalTrials.gov API (version 2) on the schedule set in the Source Registry: one broad search for obesity and incretin therapies (GLP-1, semaglutide, tirzepatide, retatrutide, orforglipron, amylin, cagrilintide, survodutide) and a separate search for each metabolic topic that has a trial query, such as retatrutide or orforglipron. Each study is stored with its registry fields exactly as published: title, phase, overall status, sponsor, conditions, interventions and the date of its last registry update.\n\nWhen a study’s overall status changes, or results are first posted, the change is recorded with the date the pipeline detected it. This tracker lists studies on the Metabolic desk whose registered phase includes phase 2 or phase 3 (combined phase 2/3 studies included). Nothing in the table is edited by hand.", "coverage": "Studies listed on ClinicalTrials.gov — from the United States and other countries — that match the search terms above, from the date tracking of each search began. Phase 2 and phase 3 only. Phase 1 and phase 4 studies, studies described with other terms and studies registered only in other registries are not included.", "limitations": "Registry records are maintained by trial sponsors and can lag events; the status shown is the sponsor’s registry status at the last check, not an assessment of the trial. Searches can include studies of these medicines for conditions other than obesity and can miss studies that use different terms. Every therapy in a trial is investigational for the use being studied. Not medical advice.", "updateFrequency": "Registry searches run every 6 to 12 hours, as configured in the Source Registry; the table reflects each completed check.", "selection": "ClinicalTrials.gov studies followed by Trial Watch in phase 2 and phase 3 on the metabolic desk.", "systemCheckedAt": "2026-11-15T17:35:05.565Z", "editoriallyReviewedAt": null, "editorialReview": "pending", "generatedAt": "2026-11-15T20:57:50.594Z", "recordCount": 181, "notAdvice": "Professional information compiled from public sources. Not medical, legal or regulatory advice; always confirm in the primary source." }, "columns": [ { "key": "phase", "label": "Phase" }, { "key": "sponsor", "label": "Sponsor" } ], "records": [ { "key": "trial:NCT06716216", "record": "A Study of BGM0504 in Participants With Type 2 Diabetes", "subtitle": "NCT06716216", "detail": "Conditions: Type 2 Diabetes Mellitus (T2DM). Interventions: Drug: 5 mg BGM0504 Administered SC; Drug:10 mg BGM0504 Administered SC; Drug: Semaglutide Administered SC", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "enrollment": "553", "nctId": "NCT06716216" }, "jurisdiction": null, "date": "2026-11-13T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06716216", "url": "https://clinicaltrials.gov/study/NCT06716216", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:09.947Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:09.965Z", "change": { "note": "Status changed from “Active, not recruiting” to “Completed”", "at": "2026-11-13T19:05:09.795Z", "withinLast7Days": true }, "origin": "automated" }, { "key": "trial:NCT06297603", "record": "Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)", "subtitle": "NCT06297603", "detail": "Conditions: Type 2 Diabetes. Interventions: Retatrutide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "320", "nctId": "NCT06297603" }, "jurisdiction": null, "date": "2026-11-13T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06297603", "url": "https://clinicaltrials.gov/study/NCT06297603", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:07.948Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:07.965Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07931573", "record": "AMBITION 3: AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both", "subtitle": "NCT07931573", "detail": "Conditions: Type 2 Diabetes. Interventions: Zenagamtide; Semaglutide; Placebo", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "1200", "nctId": "NCT07931573" }, "jurisdiction": null, "date": "2026-11-12T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07931573", "url": "https://clinicaltrials.gov/study/NCT07931573", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:09.947Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:10.307Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07931599", "record": "AMBITION4: A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both", "subtitle": "NCT07931599", "detail": "Conditions: Diabetes Mellitus, Type 2. Interventions: Zenagamtide; Semaglutide; Placebo zenagamtide; Placebo semaglutide", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "1060", "nctId": "NCT07931599" }, "jurisdiction": null, "date": "2026-11-12T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07931599", "url": "https://clinicaltrials.gov/study/NCT07931599", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:09.947Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:10.223Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07481747", "record": "SURMOUNT-1: Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)", "subtitle": "NCT07481747", "detail": "Conditions: Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities. Interventions: Tirzepatide; Placebo; Reduced-calorie diet", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Hudson Biotech", "enrollment": "2539", "nctId": "NCT07481747" }, "jurisdiction": null, "date": "2026-11-12T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07481747", "url": "https://clinicaltrials.gov/study/NCT07481747", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:08.933Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:09.237Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06299098", "record": "COURAGE: A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation", "subtitle": "NCT06299098", "detail": "Conditions: Obesity. Interventions: Trevogrumab-Part A; Trevogrumab-Part B and Part C; Garetosmab; Semaglutide; Matching Placebo-Part A; Matching Placebo-T…", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Regeneron Pharmaceuticals", "enrollment": "1005", "nctId": "NCT06299098" }, "jurisdiction": null, "date": "2026-11-12T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06299098", "url": "https://clinicaltrials.gov/study/NCT06299098", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:09.947Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:10.346Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07932925", "record": "The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight", "subtitle": "NCT07932925", "detail": "Conditions: Urinary Incontinence, Stress; Overweight and/or Obesity. Interventions: Berobenatide; Placebo", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Pfizer", "enrollment": "900", "nctId": "NCT07932925" }, "jurisdiction": null, "date": "2026-11-12T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07932925", "url": "https://clinicaltrials.gov/study/NCT07932925", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T17:35:04.137Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T17:35:05.410Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07642635", "record": "Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy", "subtitle": "NCT07642635", "detail": "Conditions: Duchenne Muscular Dystrophy (DMD). Interventions: Semaglutide (Rybelsus®); Placebo", "status": "Recruiting", "fields": { "phase": "Phase 1 / Phase 2", "sponsor": "Vanderbilt University Medical Center", "enrollment": "30", "nctId": "NCT07642635" }, "jurisdiction": null, "date": "2026-11-12T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07642635", "url": "https://clinicaltrials.gov/study/NCT07642635", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T17:35:04.137Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T17:35:04.670Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07463846", "record": "A Study to Evaluate ALN-2232 in Participants With Obesity", "subtitle": "NCT07463846", "detail": "Conditions: Obesity. Interventions: ALN-2232; Placebo; Tirzepatide", "status": "Recruiting", "fields": { "phase": "Phase 1 / Phase 2", "sponsor": "Alnylam Pharmaceuticals", "enrollment": "156", "nctId": "NCT07463846" }, "jurisdiction": null, "date": "2026-11-12T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07463846", "url": "https://clinicaltrials.gov/study/NCT07463846", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T17:35:04.137Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T17:35:04.493Z", "change": null, "origin": "automated" }, { "key": "trial:NCT00739362", "record": "Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment", "subtitle": "NCT00739362", "detail": "Conditions: Electric Stimulation Therapy; Obesity; Weight Loss; Eating. Interventions: Transcranial Direct Current Stimulation (TDCS); Sham/no-stimulation", "status": "Active, not recruiting", "fields": { "phase": "Phase 2", "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "enrollment": "126", "nctId": "NCT00739362" }, "jurisdiction": null, "date": "2026-11-12T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT00739362", "url": "https://clinicaltrials.gov/study/NCT00739362", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T17:35:04.137Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T17:35:04.840Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05556512", "record": "SURMOUNT-MMO: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity", "subtitle": "NCT05556512", "detail": "Conditions: Obesity; Overweight. Interventions: Tirzepatide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "15374", "nctId": "NCT05556512" }, "jurisdiction": null, "date": "2026-11-12T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05556512", "url": "https://clinicaltrials.gov/study/NCT05556512", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T17:35:04.137Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T17:35:05.100Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07734792", "record": "TOPAZ: Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial", "subtitle": "NCT07734792", "detail": "Conditions: Acute Ischemic Stroke (AIS). Interventions: Tirzepatide; Standard Medical Care (SMC)", "status": "Recruiting", "fields": { "phase": "Phase 2 / Phase 3", "sponsor": "yifang zhu", "enrollment": "726", "nctId": "NCT07734792" }, "jurisdiction": null, "date": "2026-11-12T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07734792", "url": "https://clinicaltrials.gov/study/NCT07734792", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T17:35:04.137Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T17:35:05.336Z", "change": { "note": "Status changed from “Not yet recruiting” to “Recruiting”", "at": "2026-11-12T18:05:05.426Z", "withinLast7Days": true }, "origin": "automated" }, { "key": "trial:NCT07112872", "record": "A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes", "subtitle": "NCT07112872", "detail": "Conditions: Type 2 Diabetes Mellitus. Interventions: Tifeglipron; Semaglutide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "Hoffmann-La Roche", "enrollment": "330", "nctId": "NCT07112872" }, "jurisdiction": null, "date": "2026-11-12T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07112872", "url": "https://clinicaltrials.gov/study/NCT07112872", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T17:35:04.137Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T17:35:05.158Z", "change": { "note": "Status changed from “Active, not recruiting” to “Recruiting”", "at": "2026-11-12T18:05:05.426Z", "withinLast7Days": true }, "origin": "automated" }, { "key": "trial:NCT07467447", "record": "GZBF: Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight", "subtitle": "NCT07467447", "detail": "Conditions: Obesity. Interventions: Retatrutide (LY3437943); Placebo; Standardized diet and physical activity counseling throughout the study.", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "Hudson Biotech", "enrollment": "300", "nctId": "NCT07467447" }, "jurisdiction": null, "date": "2026-11-12T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07467447", "url": "https://clinicaltrials.gov/study/NCT07467447", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:07.948Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:08.021Z", "change": null, "origin": "automated" }, { "key": "trial:NCT03407079", "record": "Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)", "subtitle": "NCT03407079", "detail": "Conditions: Healthy Volunteers; Overweight. Interventions: Sucralose; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", "enrollment": "150", "nctId": "NCT03407079" }, "jurisdiction": null, "date": "2026-11-12T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT03407079", "url": "https://clinicaltrials.gov/study/NCT03407079", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T17:35:04.137Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T17:35:05.047Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07850063", "record": "ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease", "subtitle": "NCT07850063", "detail": "Conditions: Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease. Interventions: Survodutide; Placebo matching survodutide", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Boehringer Ingelheim", "enrollment": "600", "nctId": "NCT07850063" }, "jurisdiction": null, "date": "2026-11-12T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07850063", "url": "https://clinicaltrials.gov/study/NCT07850063", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T17:35:04.137Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T17:35:04.336Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06077864", "record": "A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)", "subtitle": "NCT06077864", "detail": "Conditions: Obesity. Interventions: survodutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Boehringer Ingelheim", "enrollment": "5530", "nctId": "NCT06077864" }, "jurisdiction": null, "date": "2026-11-12T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06077864", "url": "https://clinicaltrials.gov/study/NCT06077864", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T17:35:04.137Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T17:35:04.893Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06778967", "record": "Optimum 2: A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus", "subtitle": "NCT06778967", "detail": "Conditions: Type 2 Diabetes Mellitus (T2DM). Interventions: GZR18; semaglutide", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Gan & Lee Pharmaceuticals.", "enrollment": "1133", "nctId": "NCT06778967" }, "jurisdiction": null, "date": "2026-11-10T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06778967", "url": "https://clinicaltrials.gov/study/NCT06778967", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:09.947Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:10.612Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07292441", "record": "GZR18-BWM-303: Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss", "subtitle": "NCT07292441", "detail": "Conditions: Overweight or Obesity. Interventions: GZR18 injection; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Gan & Lee Pharmaceuticals.", "enrollment": "224", "nctId": "NCT07292441" }, "jurisdiction": null, "date": "2026-11-10T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07292441", "url": "https://clinicaltrials.gov/study/NCT07292441", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T11:35:12.390Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T11:35:12.841Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07929298", "record": "A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity", "subtitle": "NCT07929298", "detail": "Conditions: Overweight , Obesity; Weight Management. Interventions: ecnoglutide tablet; placebo with matching dosage", "status": "Not yet recruiting", "fields": { "phase": "Phase 2", "sponsor": "Hangzhou Sciwind Biosciences Co., Ltd.", "enrollment": "180", "nctId": "NCT07929298" }, "jurisdiction": null, "date": "2026-11-10T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07929298", "url": "https://clinicaltrials.gov/study/NCT07929298", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T11:35:12.390Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T11:35:12.751Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07830329", "record": "Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity", "subtitle": "NCT07830329", "detail": "Conditions: Hidradenitis Suppurativa. Interventions: Olatorepatide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "Regeneron Pharmaceuticals", "enrollment": "300", "nctId": "NCT07830329" }, "jurisdiction": null, "date": "2026-11-10T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07830329", "url": "https://clinicaltrials.gov/study/NCT07830329", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T11:35:12.390Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T11:35:12.659Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06162715", "record": "GRABS-0: GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial", "subtitle": "NCT06162715", "detail": "Conditions: Severe Obesity; Obesity; BMI Greater Than 30. Interventions: Tirzepatide; Standard of Care post-gastric bypass", "status": "Active, not recruiting", "fields": { "phase": "Phase 2 / Phase 3", "sponsor": "Vanderbilt University Medical Center", "enrollment": "30", "nctId": "NCT06162715" }, "jurisdiction": null, "date": "2026-11-10T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06162715", "url": "https://clinicaltrials.gov/study/NCT06162715", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:08.933Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:09.277Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07400107", "record": "AMAZE 8: AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight", "subtitle": "NCT07400107", "detail": "Conditions: Obesity; Overweight; Diabetes Mellitus, Type 2. Interventions: NNC0487-0111; Semaglutide; Placebo (matched to NNC0487-0111); Placebo (matched to semaglutide)", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "985", "nctId": "NCT07400107" }, "jurisdiction": null, "date": "2026-11-10T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07400107", "url": "https://clinicaltrials.gov/study/NCT07400107", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:09.947Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:10.529Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07232719", "record": "TRIUMPH-8: A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight", "subtitle": "NCT07232719", "detail": "Conditions: Obesity; Overweight. Interventions: Retatrutide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "250", "nctId": "NCT07232719" }, "jurisdiction": null, "date": "2026-11-10T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07232719", "url": "https://clinicaltrials.gov/study/NCT07232719", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:07.948Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:08.065Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07351045", "record": "Enith1: A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes", "subtitle": "NCT07351045", "detail": "Conditions: Obesity or Overweight. Interventions: Placebo; Enicepatide", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Hoffmann-La Roche", "enrollment": "2000", "nctId": "NCT07351045" }, "jurisdiction": null, "date": "2026-11-09T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07351045", "url": "https://clinicaltrials.gov/study/NCT07351045", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T11:35:12.390Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T11:35:12.984Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07351058", "record": "Enith2: A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes", "subtitle": "NCT07351058", "detail": "Conditions: Obesity or Overweight; Type 2 Diabetes Mellitus. Interventions: Placebo; Enicepatide", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Hoffmann-La Roche", "enrollment": "1600", "nctId": "NCT07351058" }, "jurisdiction": null, "date": "2026-11-09T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07351058", "url": "https://clinicaltrials.gov/study/NCT07351058", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T11:35:12.390Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T11:35:13.206Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07775404", "record": "Elecoglipron: A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus", "subtitle": "NCT07775404", "detail": "Conditions: Obesity; Overweight. Interventions: Elecoglipron; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "AstraZeneca", "enrollment": "351", "nctId": "NCT07775404" }, "jurisdiction": null, "date": "2026-11-09T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07775404", "url": "https://clinicaltrials.gov/study/NCT07775404", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T11:35:12.390Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T11:35:12.885Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05936151", "record": "A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes", "subtitle": "NCT05936151", "detail": "Conditions: Overweight or Obesity; CKD; Type 2 Diabetes. Interventions: Retatrutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Eli Lilly and Company", "enrollment": "146", "nctId": "NCT05936151" }, "jurisdiction": null, "date": "2026-11-09T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05936151", "url": "https://clinicaltrials.gov/study/NCT05936151", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:07.948Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:08.105Z", "change": { "note": "Results first posted on ClinicalTrials.gov (2026-11-09)", "at": "2026-11-09T14:35:06.951Z", "withinLast7Days": true }, "origin": "automated" }, { "key": "trial:NCT07923357", "record": "A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus", "subtitle": "NCT07923357", "detail": "Conditions: Type 2 Diabetes Mellitus (T2DM); Type 2 Diabetes; T2DM. Interventions: SAL0150 dose 1; SAL0150 dose 2; SAL0150 dose 2; SAL0150 dose 3; SAL0150 dose 3; Placebo; Semaglutide inject 1.0 mg", "status": "Not yet recruiting", "fields": { "phase": "Phase 2", "sponsor": "Shenzhen Salubris Pharmaceuticals Co., Ltd.", "enrollment": "364", "nctId": "NCT07923357" }, "jurisdiction": null, "date": "2026-11-06T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07923357", "url": "https://clinicaltrials.gov/study/NCT07923357", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:09.947Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:10.874Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07923630", "record": "VITAL-H: Validation & Intervention Testing for Aging, Longevity and Healthspan", "subtitle": "NCT07923630", "detail": "Conditions: Aging; Functional Decline. Interventions: Dapagliflozin 10Mg Oral Tablet; Semaglutide oral; Placebo", "status": "Not yet recruiting", "fields": { "phase": "Phase 2", "sponsor": "The University of Texas Health Science Center at San Antonio", "enrollment": "1200", "nctId": "NCT07923630" }, "jurisdiction": null, "date": "2026-11-06T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07923630", "url": "https://clinicaltrials.gov/study/NCT07923630", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T06:05:03.507Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T06:05:04.046Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07651319", "record": "Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease", "subtitle": "NCT07651319", "detail": "Conditions: Alzheimer Dementia (AD). Interventions: IL-2 (Aldesleukin); Semaglutide Plus IL-2; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 1 / Phase 2", "sponsor": "The Methodist Hospital Research Institute", "enrollment": "30", "nctId": "NCT07651319" }, "jurisdiction": null, "date": "2026-11-06T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07651319", "url": "https://clinicaltrials.gov/study/NCT07651319", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-13T06:35:13.538Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-13T06:35:14.557Z", "change": null, "origin": "automated" }, { "key": "trial:NCT04873245", "record": "QUEST: Lifestyle Counseling and Medication for Adolescent Weight Management", "subtitle": "NCT04873245", "detail": "Conditions: Obesity, Childhood. Interventions: Intensive Behavioral Program; Semaglutide and Behavioral Program", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "University of Minnesota", "enrollment": "121", "nctId": "NCT04873245" }, "jurisdiction": null, "date": "2026-11-06T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT04873245", "url": "https://clinicaltrials.gov/study/NCT04873245", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T06:05:03.507Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T06:05:03.939Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07575399", "record": "Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)", "subtitle": "NCT07575399", "detail": "Conditions: Obesity or Overweight. Interventions: Maridebart Cafraglutide", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Amgen", "enrollment": "300", "nctId": "NCT07575399" }, "jurisdiction": null, "date": "2026-11-06T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07575399", "url": "https://clinicaltrials.gov/study/NCT07575399", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-10T09:35:10.280Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-10T09:35:10.831Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07685808", "record": "Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes", "subtitle": "NCT07685808", "detail": "Conditions: Overweight or Obesity. Interventions: Olatorepatide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "Regeneron Pharmaceuticals", "enrollment": "360", "nctId": "NCT07685808" }, "jurisdiction": null, "date": "2026-11-06T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07685808", "url": "https://clinicaltrials.gov/study/NCT07685808", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T11:35:12.390Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T11:35:13.493Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07163624", "record": "T2DM: UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study", "subtitle": "NCT07163624", "detail": "Conditions: Type 2 Diabetes Mellitus (T2DM). Interventions: UBT251 Injection 2.0 mg and UBT251 Injection Placebo; UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo;…", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "The United Bio-Technology (Hengqin) Co., Ltd.", "enrollment": "211", "nctId": "NCT07163624" }, "jurisdiction": null, "date": "2026-11-05T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07163624", "url": "https://clinicaltrials.gov/study/NCT07163624", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T06:05:03.507Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T06:05:04.147Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06913023", "record": "SPOT-DM: Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus", "subtitle": "NCT06913023", "detail": "Conditions: Kidney Transplant Recipient. Interventions: Semaglutide 0.25 mg; Semaglutide 0.5 mg; Semaglutide 1.0 mg; Semaglutide 1.7mg subcutaneous; Semaglutide 2.4 MG/0.75 ML…", "status": "Not yet recruiting", "fields": { "phase": "Phase 2 / Phase 3", "sponsor": "University Health Network, Toronto", "enrollment": "37", "nctId": "NCT06913023" }, "jurisdiction": null, "date": "2026-11-05T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06913023", "url": "https://clinicaltrials.gov/study/NCT06913023", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T06:05:03.507Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T06:05:04.114Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07919405", "record": "REDEFINE: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity", "subtitle": "NCT07919405", "detail": "Conditions: Hypertension; Obesity. Interventions: CagriSema; Semaglutide; Cagrilintide; Placebo", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "1408", "nctId": "NCT07919405" }, "jurisdiction": null, "date": "2026-11-05T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07919405", "url": "https://clinicaltrials.gov/study/NCT07919405", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.068Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:05.158Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07918846", "record": "Enith-MACE: A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease", "subtitle": "NCT07918846", "detail": "Conditions: Overweight; Obesity; Cardiovascular Disease. Interventions: Enicepatide; Placebo", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Hoffmann-La Roche", "enrollment": "8200", "nctId": "NCT07918846" }, "jurisdiction": null, "date": "2026-11-05T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07918846", "url": "https://clinicaltrials.gov/study/NCT07918846", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-10T09:35:10.280Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-10T09:35:11.048Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06973720", "record": "VESPER-3: A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight", "subtitle": "NCT06973720", "detail": "Conditions: Obesity; Overweight or Obesity. Interventions: MET097; Placebo", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Pfizer", "enrollment": "268", "nctId": "NCT06973720" }, "jurisdiction": null, "date": "2026-11-05T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06973720", "url": "https://clinicaltrials.gov/study/NCT06973720", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-09T08:05:04.880Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-09T08:05:05.516Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07919678", "record": "A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)", "subtitle": "NCT07919678", "detail": "Conditions: Obesity; Overweight; Osteoarthritis of the Knee. Interventions: Berobenatide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Pfizer", "enrollment": "656", "nctId": "NCT07919678" }, "jurisdiction": null, "date": "2026-11-05T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07919678", "url": "https://clinicaltrials.gov/study/NCT07919678", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-09T08:05:04.880Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-09T08:05:05.250Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07866066", "record": "MARITIME-T2D-3: Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes", "subtitle": "NCT07866066", "detail": "Conditions: Diabetes Mellitus, Type 2. Interventions: Maridebart cafraglutide; Semaglutide", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Amgen", "enrollment": "1300", "nctId": "NCT07866066" }, "jurisdiction": null, "date": "2026-11-05T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07866066", "url": "https://clinicaltrials.gov/study/NCT07866066", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T06:05:03.507Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T06:05:04.224Z", "change": { "note": "Status changed from “Not yet recruiting” to “Recruiting”", "at": "2026-11-05T15:35:04.481Z", "withinLast7Days": false }, "origin": "automated" }, { "key": "trial:NCT07670416", "record": "A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes", "subtitle": "NCT07670416", "detail": "Conditions: Obesity; Overweight; Type 2 Diabetes Mellitus (T2DM). Interventions: Enicepatide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Hoffmann-La Roche", "enrollment": "300", "nctId": "NCT07670416" }, "jurisdiction": null, "date": "2026-11-05T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07670416", "url": "https://clinicaltrials.gov/study/NCT07670416", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-09T08:05:04.880Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-09T08:05:05.378Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07668336", "record": "ACHIEVE-PEDS: A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes", "subtitle": "NCT07668336", "detail": "Conditions: Diabetes Mellitus, Type 2. Interventions: Orforglipron; Dulaglutide", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "170", "nctId": "NCT07668336" }, "jurisdiction": null, "date": "2026-11-05T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07668336", "url": "https://clinicaltrials.gov/study/NCT07668336", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.987Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:06.001Z", "change": { "note": "Status changed from “Not yet recruiting” to “Recruiting”", "at": "2026-10-19T23:35:08.309Z", "withinLast7Days": false }, "origin": "automated" }, { "key": "trial:NCT07794579", "record": "ATTAIN-NOW: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity", "subtitle": "NCT07794579", "detail": "Conditions: Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal. Interventions: Orforglipron; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "2001", "nctId": "NCT07794579" }, "jurisdiction": null, "date": "2026-11-05T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07794579", "url": "https://clinicaltrials.gov/study/NCT07794579", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.987Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:06.040Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07575932", "record": "SOLIS-1: A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity", "subtitle": "NCT07575932", "detail": "Conditions: Overweight; Obesity; Overweight and/or Obesity; Overweight or Obesity; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseas…. Interventions: PF-08653945; PF-08653944; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 2", "sponsor": "Pfizer", "enrollment": "940", "nctId": "NCT07575932" }, "jurisdiction": null, "date": "2026-11-05T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07575932", "url": "https://clinicaltrials.gov/study/NCT07575932", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.068Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:05.121Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07845500", "record": "A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity", "subtitle": "NCT07845500", "detail": "Conditions: Obesity; Overweight and/or Obesity; Overweight; Treatment Of Obesity. Interventions: Semaglutide; Berobenatide; Tirzepatide", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Pfizer", "enrollment": "660", "nctId": "NCT07845500" }, "jurisdiction": null, "date": "2026-11-05T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07845500", "url": "https://clinicaltrials.gov/study/NCT07845500", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:08.933Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:09.556Z", "change": { "note": "Status changed from “Not yet recruiting” to “Recruiting”", "at": "2026-10-15T14:35:04.243Z", "withinLast7Days": false }, "origin": "automated" }, { "key": "trial:NCT07915609", "record": "A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)", "subtitle": "NCT07915609", "detail": "Conditions: Obesity; Overweight and/or Obesity; Knee Osteoarthritis; Diabetes Melliuts, Type 2. Interventions: Berobenatide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Pfizer", "enrollment": "756", "nctId": "NCT07915609" }, "jurisdiction": null, "date": "2026-11-04T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07915609", "url": "https://clinicaltrials.gov/study/NCT07915609", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-05T13:05:06.094Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-05T13:05:06.398Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07295223", "record": "GALACTUS: Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)", "subtitle": "NCT07295223", "detail": "Conditions: Acute Myocardial Infarction With ST Elevation. Interventions: Dapagliflozin 10 MG Oral Tablet; Semaglutide (Rybelsus®)", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Instituto Mexicano del Seguro Social", "enrollment": "44", "nctId": "NCT07295223" }, "jurisdiction": null, "date": "2026-11-04T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07295223", "url": "https://clinicaltrials.gov/study/NCT07295223", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-10T04:35:08.468Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-10T04:35:08.984Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06975111", "record": "Focusing on the Menopausal Transition to Improve Mid-Life Women's Health", "subtitle": "NCT06975111", "detail": "Conditions: Menopause; Menopause Hot Flashes; Menopause Related Conditions; Cardiovascular. Interventions: Metformin; semaglutide; Anti-hypertensives; Lipid Lowering Medication; Life style intervention; Fezolinetant; Hormonal…", "status": "Recruiting", "fields": { "phase": "Phase 2 / Phase 3", "sponsor": "University of Colorado, Denver", "enrollment": "200", "nctId": "NCT06975111" }, "jurisdiction": null, "date": "2026-11-04T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06975111", "url": "https://clinicaltrials.gov/study/NCT06975111", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-10T04:35:08.468Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-10T04:35:09.047Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07881458", "record": "AMPLIFY-2: A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes", "subtitle": "NCT07881458", "detail": "Conditions: Obesity; Overweight; Diabetes Mellitus, Type 2. Interventions: eloralintide and tirzepatide; Tirzepatide", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "1000", "nctId": "NCT07881458" }, "jurisdiction": null, "date": "2026-11-04T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07881458", "url": "https://clinicaltrials.gov/study/NCT07881458", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:08.933Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:09.640Z", "change": { "note": "Status changed from “Not yet recruiting” to “Recruiting”", "at": "2026-11-04T14:05:05.626Z", "withinLast7Days": false }, "origin": "automated" }, { "key": "trial:NCT05500586", "record": "The Effects of Glucagon on Hepatic Metabolism", "subtitle": "NCT05500586", "detail": "Conditions: Obesity; Type2diabetes; NAFLD. Interventions: Glucagon response study", "status": "Completed", "fields": { "phase": "Phase 1 / Phase 2", "sponsor": "Adrian Vella", "enrollment": "21", "nctId": "NCT05500586" }, "jurisdiction": null, "date": "2026-11-04T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05500586", "url": "https://clinicaltrials.gov/study/NCT05500586", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-05T13:05:06.094Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-05T13:05:06.156Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06897475", "record": "A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide", "subtitle": "NCT06897475", "detail": "Conditions: Type 2 Diabetes. Interventions: LY3457263; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "Eli Lilly and Company", "enrollment": "200", "nctId": "NCT06897475" }, "jurisdiction": null, "date": "2026-11-04T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06897475", "url": "https://clinicaltrials.gov/study/NCT06897475", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T05:35:13.895Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T05:35:14.207Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06937099", "record": "COMMIT-CD: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight", "subtitle": "NCT06937099", "detail": "Conditions: Crohn's Disease; Obesity or Overweight. Interventions: Mirikizumab; Mirikizumab; Tirzepatide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "290", "nctId": "NCT06937099" }, "jurisdiction": null, "date": "2026-11-04T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06937099", "url": "https://clinicaltrials.gov/study/NCT06937099", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:08.933Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:09.769Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06937086", "record": "COMMIT-UC: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study", "subtitle": "NCT06937086", "detail": "Conditions: Ulcerative Colitis; Obesity or Overweight. Interventions: Mirikizumab; Mirikizumab; Tirzepatide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "350", "nctId": "NCT06937086" }, "jurisdiction": null, "date": "2026-11-04T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06937086", "url": "https://clinicaltrials.gov/study/NCT06937086", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-13T06:35:12.284Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-13T06:35:13.148Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07817875", "record": "Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)", "subtitle": "NCT07817875", "detail": "Conditions: Obesity. Interventions: Tirzepatide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "150", "nctId": "NCT07817875" }, "jurisdiction": null, "date": "2026-11-04T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07817875", "url": "https://clinicaltrials.gov/study/NCT07817875", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:08.933Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:09.720Z", "change": { "note": "Status changed from “Not yet recruiting” to “Recruiting”", "at": "2026-10-13T18:05:01.705Z", "withinLast7Days": false }, "origin": "automated" }, { "key": "trial:NCT06672939", "record": "A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities", "subtitle": "NCT06672939", "detail": "Conditions: Obesity; Overweight. Interventions: Orforglipron; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "150", "nctId": "NCT06672939" }, "jurisdiction": null, "date": "2026-11-04T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06672939", "url": "https://clinicaltrials.gov/study/NCT06672939", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.987Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:06.119Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07202884", "record": "RESTRAIN-SUI: A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight", "subtitle": "NCT07202884", "detail": "Conditions: Urinary Incontinence,Stress. Interventions: Orforglipron; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "1000", "nctId": "NCT07202884" }, "jurisdiction": null, "date": "2026-11-04T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07202884", "url": "https://clinicaltrials.gov/study/NCT07202884", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.987Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:06.200Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07223593", "record": "ATTAIN-PAD: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease", "subtitle": "NCT07223593", "detail": "Conditions: Peripheral Arterial Disease. Interventions: Orforglipron; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "1205", "nctId": "NCT07223593" }, "jurisdiction": null, "date": "2026-11-04T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07223593", "url": "https://clinicaltrials.gov/study/NCT07223593", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.987Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:06.238Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07241390", "record": "A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)", "subtitle": "NCT07241390", "detail": "Conditions: Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease. Interventions: Orforglipron; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "7140", "nctId": "NCT07241390" }, "jurisdiction": null, "date": "2026-11-04T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07241390", "url": "https://clinicaltrials.gov/study/NCT07241390", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.987Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:06.079Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06672549", "record": "ADVANCE: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)", "subtitle": "NCT06672549", "detail": "Conditions: Obesity; Overweight. Interventions: Orforglipron; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "125", "nctId": "NCT06672549" }, "jurisdiction": null, "date": "2026-11-04T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06672549", "url": "https://clinicaltrials.gov/study/NCT06672549", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.987Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:06.160Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07392190", "record": "ENLIGHTEN-6: A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin", "subtitle": "NCT07392190", "detail": "Conditions: Overweight; Obesity. Interventions: Eloralintide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "900", "nctId": "NCT07392190" }, "jurisdiction": null, "date": "2026-11-04T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07392190", "url": "https://clinicaltrials.gov/study/NCT07392190", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.068Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:05.199Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07734870", "record": "Tirzepatide for Treatment of CCCA", "subtitle": "NCT07734870", "detail": "Conditions: Central Centrifugal Cicatricial Alopecia (CCCA). Interventions: Tirzepatide", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "Johns Hopkins University", "enrollment": "20", "nctId": "NCT07734870" }, "jurisdiction": null, "date": "2026-11-03T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07734870", "url": "https://clinicaltrials.gov/study/NCT07734870", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T05:35:13.895Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T05:35:14.291Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07767942", "record": "UNISHAPE-OSA-1: UBT251 Injection Phase Ⅲ Study (OSA-NPAP)", "subtitle": "NCT07767942", "detail": "Conditions: Obstructive Sleep Apnea, Obesity. Interventions: UBT251; UBT251; Placebo", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "The United Bio-Technology (Hengqin) Co., Ltd.", "enrollment": "150", "nctId": "NCT07767942" }, "jurisdiction": null, "date": "2026-11-03T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07767942", "url": "https://clinicaltrials.gov/study/NCT07767942", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-05T13:05:06.094Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-05T13:05:06.779Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07890376", "record": "A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes", "subtitle": "NCT07890376", "detail": "Conditions: Obesity; Overweight. Interventions: LY4086940; Placebo", "status": "Not yet recruiting", "fields": { "phase": "Phase 2", "sponsor": "Eli Lilly and Company", "enrollment": "460", "nctId": "NCT07890376" }, "jurisdiction": null, "date": "2026-11-03T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07890376", "url": "https://clinicaltrials.gov/study/NCT07890376", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-05T13:05:06.094Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-05T13:05:06.739Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07881432", "record": "AMPLIFY-1: A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes", "subtitle": "NCT07881432", "detail": "Conditions: Obesity. Interventions: eloralintide and tirzepatide; Eloralintide; Tirzepatide; Placebo", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "2115", "nctId": "NCT07881432" }, "jurisdiction": null, "date": "2026-11-03T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07881432", "url": "https://clinicaltrials.gov/study/NCT07881432", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T05:35:13.895Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T05:35:14.347Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07909889", "record": "WISPER: Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer", "subtitle": "NCT07909889", "detail": "Conditions: Breast Cancer (Early Breast Cancer); Obesity. Interventions: Semaglutide (Wegovy®)", "status": "Not yet recruiting", "fields": { "phase": "Phase 2", "sponsor": "Aarhus University Hospital", "enrollment": "32", "nctId": "NCT07909889" }, "jurisdiction": null, "date": "2026-11-02T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07909889", "url": "https://clinicaltrials.gov/study/NCT07909889", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-06T13:35:13.317Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-06T13:35:14.088Z", "change": null, "origin": "automated" }, { "key": "trial:NCT04916470", "record": "STEP HFpEF DM: Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes", "subtitle": "NCT04916470", "detail": "Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2. Interventions: Semaglutide; Placebo (Semaglutide)", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "617", "nctId": "NCT04916470" }, "jurisdiction": null, "date": "2026-11-02T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT04916470", "url": "https://clinicaltrials.gov/study/NCT04916470", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-09T03:35:10.793Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-09T03:35:11.558Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06924320", "record": "A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes", "subtitle": "NCT06924320", "detail": "Conditions: Obesity and Obesity-related Medical Conditions. Interventions: MET233 and MET097; Placebo; MET097", "status": "Completed", "fields": { "phase": "Phase 1 / Phase 2", "sponsor": "Pfizer", "enrollment": "201", "nctId": "NCT06924320" }, "jurisdiction": null, "date": "2026-11-02T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06924320", "url": "https://clinicaltrials.gov/study/NCT06924320", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-05T13:05:06.094Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-05T13:05:06.922Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07906041", "record": "Tirzepatide and Organ-specific Biological Aging", "subtitle": "NCT07906041", "detail": "Conditions: Longevity; Preventive Medicine; Biological Ageing. Interventions: Tirzepatide", "status": "Enrolling by invitation", "fields": { "phase": "Phase 2", "sponsor": "Atria Research and Global Health Institute (ARGHI)", "enrollment": "22", "nctId": "NCT07906041" }, "jurisdiction": null, "date": "2026-11-02T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07906041", "url": "https://clinicaltrials.gov/study/NCT07906041", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T05:35:13.895Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T05:35:14.431Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07907965", "record": "A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease", "subtitle": "NCT07907965", "detail": "Conditions: Diabetic Kidney Disease (DKD); Type 2 Diabetes; Albuminuria. Interventions: Guominkang Granules; Standard Antihypertensive, Antidiabetic, and Lipid-Lowering Regimen", "status": "Active, not recruiting", "fields": { "phase": "Phase 2", "sponsor": "Beijing University of Chinese Medicine", "enrollment": "15", "nctId": "NCT07907965" }, "jurisdiction": null, "date": "2026-11-02T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07907965", "url": "https://clinicaltrials.gov/study/NCT07907965", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:06.920Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:07.140Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07846865", "record": "TIRZE-PAP: Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea", "subtitle": "NCT07846865", "detail": "Conditions: Sleep Apnoea; Obesity & Overweight; Sleep Apnea Syndrome, Obstructive. Interventions: Continuous Positive Airway Pressure; Tirzepatide", "status": "Not yet recruiting", "fields": { "phase": "Phase 2 / Phase 3", "sponsor": "Woolcock Institute of Medical Research", "enrollment": "256", "nctId": "NCT07846865" }, "jurisdiction": null, "date": "2026-11-02T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07846865", "url": "https://clinicaltrials.gov/study/NCT07846865", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T05:35:13.895Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T05:35:14.377Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06700538", "record": "A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus", "subtitle": "NCT06700538", "detail": "Conditions: Obesity. Interventions: ARO-INHBE; Placebo; Tirzepatide", "status": "Active, not recruiting", "fields": { "phase": "Phase 1 / Phase 2", "sponsor": "Arrowhead Pharmaceuticals", "enrollment": "190", "nctId": "NCT06700538" }, "jurisdiction": null, "date": "2026-10-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06700538", "url": "https://clinicaltrials.gov/study/NCT06700538", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-10T04:35:07.703Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-10T04:35:08.226Z", "change": { "note": "Status changed from “Recruiting” to “Active, not recruiting”", "at": "2026-10-30T13:35:10.982Z", "withinLast7Days": false }, "origin": "automated" }, { "key": "trial:NCT07850050", "record": "SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight", "subtitle": "NCT07850050", "detail": "Conditions: Obesity. Interventions: Survodutide; Placebo", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Boehringer Ingelheim", "enrollment": "600", "nctId": "NCT07850050" }, "jurisdiction": null, "date": "2026-10-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07850050", "url": "https://clinicaltrials.gov/study/NCT07850050", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-04T08:05:04.219Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-04T08:05:05.059Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07693608", "record": "TRI-MR: An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder", "subtitle": "NCT07693608", "detail": "Conditions: Obesity; Methamphetamine Use Disorder; Cocaine Use Disorder; Stimulant Use Disorders. Interventions: Tirzepatide", "status": "Active, not recruiting", "fields": { "phase": "Phase 2", "sponsor": "University of Texas Southwestern Medical Center", "enrollment": "45", "nctId": "NCT07693608" }, "jurisdiction": null, "date": "2026-10-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07693608", "url": "https://clinicaltrials.gov/study/NCT07693608", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-10T04:35:07.703Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-10T04:35:08.330Z", "change": null, "origin": "automated" }, { "key": "trial:NCT04466566", "record": "A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics", "subtitle": "NCT04466566", "detail": "Conditions: Healthy. Interventions: Saline; Exendin-9,39; Liraglutide", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Adrian Vella", "enrollment": "21", "nctId": "NCT04466566" }, "jurisdiction": null, "date": "2026-10-28T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT04466566", "url": "https://clinicaltrials.gov/study/NCT04466566", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:06.920Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:07.293Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06632444", "record": "LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis", "subtitle": "NCT06632444", "detail": "Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH); Liver Fibrosis. Interventions: Survodutide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Boehringer Ingelheim", "enrollment": "1800", "nctId": "NCT06632444" }, "jurisdiction": null, "date": "2026-10-28T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06632444", "url": "https://clinicaltrials.gov/study/NCT06632444", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-02T10:35:05.531Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-02T10:35:06.271Z", "change": null, "origin": "automated" }, { "key": "trial:NCT03884075", "record": "Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)", "subtitle": "NCT03884075", "detail": "Conditions: Non-Alcoholic Steatohepatitis; Non-Alcoholic Fatty Liver Disease. Interventions: Semaglutide", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "enrollment": "104", "nctId": "NCT03884075" }, "jurisdiction": null, "date": "2026-10-27T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT03884075", "url": "https://clinicaltrials.gov/study/NCT03884075", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-05T13:05:12.219Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-05T13:05:12.904Z", "change": null, "origin": "automated" }, { "key": "trial:NCT04019197", "record": "Effects of Semaglutide in HIV-Associated Lipohypertrophy", "subtitle": "NCT04019197", "detail": "Conditions: HIV/AIDS; Lipohypertrophy; Obesity. Interventions: Semaglutide Injectable Product; Placebo", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Case Western Reserve University", "enrollment": "108", "nctId": "NCT04019197" }, "jurisdiction": null, "date": "2026-10-27T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT04019197", "url": "https://clinicaltrials.gov/study/NCT04019197", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-05T13:05:12.219Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-05T13:05:12.943Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07220629", "record": "RESOLVE-2: Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)", "subtitle": "NCT07220629", "detail": "Conditions: Obesity. Interventions: NT-0796; Placebo", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Rezera (formerly NodThera Limited)", "enrollment": "82", "nctId": "NCT07220629" }, "jurisdiction": null, "date": "2026-10-27T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07220629", "url": "https://clinicaltrials.gov/study/NCT07220629", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-05T13:05:12.219Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-05T13:05:13.032Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07897383", "record": "H24LEAP2: Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity", "subtitle": "NCT07897383", "detail": "Conditions: Obesity & Overweight. Interventions: Liver-expressed antimicrobial peptide 2; Placebo", "status": "Not yet recruiting", "fields": { "phase": "Phase 1 / Phase 2", "sponsor": "University Hospital, Gentofte, Copenhagen", "enrollment": "18", "nctId": "NCT07897383" }, "jurisdiction": null, "date": "2026-10-27T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07897383", "url": "https://clinicaltrials.gov/study/NCT07897383", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-02T10:35:05.531Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-02T10:35:06.480Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07855900", "record": "SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight", "subtitle": "NCT07855900", "detail": "Conditions: Obesity. Interventions: Survodutide", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Boehringer Ingelheim", "enrollment": "350", "nctId": "NCT07855900" }, "jurisdiction": null, "date": "2026-10-27T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07855900", "url": "https://clinicaltrials.gov/study/NCT07855900", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-05T13:05:12.219Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-05T13:05:12.992Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07752979", "record": "Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities", "subtitle": "NCT07752979", "detail": "Conditions: Obesity; Overweight. Interventions: ABBV-295; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "AbbVie", "enrollment": "360", "nctId": "NCT07752979" }, "jurisdiction": null, "date": "2026-10-27T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07752979", "url": "https://clinicaltrials.gov/study/NCT07752979", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.068Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:05.237Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07825857", "record": "T-STEM: Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder", "subtitle": "NCT07825857", "detail": "Conditions: Methamphetamine Use Disorder. Interventions: Tirzepatide; Placebo (saline)", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "University of Texas Southwestern Medical Center", "enrollment": "228", "nctId": "NCT07825857" }, "jurisdiction": null, "date": "2026-10-26T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07825857", "url": "https://clinicaltrials.gov/study/NCT07825857", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-04T12:05:09.561Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-04T12:05:10.143Z", "change": null, "origin": "automated" }, { "key": "trial:NCT04535960", "record": "NATRIURETIC: Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: \"NATRIURETIC\" Trial", "subtitle": "NCT04535960", "detail": "Conditions: Type 2 Diabetes Mellitus. Interventions: Empagliflozin 25 MG + Liraglutide 1.8 MG; Liraglutide 1.8 MG + Empagliflozin 25 MG", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "University Health Network, Toronto", "enrollment": "6", "nctId": "NCT04535960" }, "jurisdiction": null, "date": "2026-10-26T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT04535960", "url": "https://clinicaltrials.gov/study/NCT04535960", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:06.920Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:07.376Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05073835", "record": "BARI-STEP: Semaglutide 2.4 mg in Patients With Poor Weight-loss", "subtitle": "NCT05073835", "detail": "Conditions: Obesity; Diabetes; Metabolic Syndrome. Interventions: Semaglutide 3 mg; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "University College, London", "enrollment": "70", "nctId": "NCT05073835" }, "jurisdiction": null, "date": "2026-10-26T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05073835", "url": "https://clinicaltrials.gov/study/NCT05073835", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-04T12:05:10.340Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-04T12:05:10.991Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07896265", "record": "RISE-1: Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes", "subtitle": "NCT07896265", "detail": "Conditions: Overweight or Obesity Without Diabetes. Interventions: Olatorepatide; Placebo", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Regeneron Pharmaceuticals", "enrollment": "3000", "nctId": "NCT07896265" }, "jurisdiction": null, "date": "2026-10-26T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07896265", "url": "https://clinicaltrials.gov/study/NCT07896265", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-30T07:05:45.278Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-30T07:05:45.888Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06842186", "record": "INLIGHT: A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity", "subtitle": "NCT06842186", "detail": "Conditions: Overweight and Obesity. Interventions: WVE-007", "status": "Recruiting", "fields": { "phase": "Phase 1 / Phase 2", "sponsor": "Wave Life Sciences USA, Inc.", "enrollment": "400", "nctId": "NCT06842186" }, "jurisdiction": null, "date": "2026-10-26T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06842186", "url": "https://clinicaltrials.gov/study/NCT06842186", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-04T12:05:09.561Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-04T12:05:10.192Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07891156", "record": "SEMA-T1D-BODY: Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.", "subtitle": "NCT07891156", "detail": "Conditions: Type 1 Diabetes; Overweight , Obesity. Interventions: Semaglutide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 2 / Phase 3", "sponsor": "McGill University Health Centre/Research Institute of the McGill University Health Centre", "enrollment": "40", "nctId": "NCT07891156" }, "jurisdiction": null, "date": "2026-10-23T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07891156", "url": "https://clinicaltrials.gov/study/NCT07891156", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-04T12:05:10.340Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-04T12:05:11.070Z", "change": null, "origin": "automated" }, { "key": "trial:NCT04578652", "record": "Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance", "subtitle": "NCT04578652", "detail": "Conditions: Obesity, Childhood; Insulin Resistance. Interventions: Metformin 850 mg oral tablet bid; Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resi…", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "University of Alberta", "enrollment": "90", "nctId": "NCT04578652" }, "jurisdiction": null, "date": "2026-10-23T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT04578652", "url": "https://clinicaltrials.gov/study/NCT04578652", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-28T10:35:04.727Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-28T10:35:06.223Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06151964", "record": "CONTEMPO: A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight", "subtitle": "NCT06151964", "detail": "Conditions: Overweight and Obesity. Interventions: AZD9550; placebo; AZD9550 and AZD6234", "status": "Active, not recruiting", "fields": { "phase": "Phase 1 / Phase 2", "sponsor": "AstraZeneca", "enrollment": "166", "nctId": "NCT06151964" }, "jurisdiction": null, "date": "2026-10-23T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06151964", "url": "https://clinicaltrials.gov/study/NCT06151964", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-28T10:35:04.727Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-28T10:35:05.931Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07225829", "record": "INFLAM MOTION: A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis", "subtitle": "NCT07225829", "detail": "Conditions: Knee Osteoarthritis; Synovitis of Knee. Interventions: 4P004; Placebo (NaCl 0.9%)", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "4Moving Biotech", "enrollment": "130", "nctId": "NCT07225829" }, "jurisdiction": null, "date": "2026-10-23T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07225829", "url": "https://clinicaltrials.gov/study/NCT07225829", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:06.920Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:07.458Z", "change": { "note": "Status changed from “Active, not recruiting” to “Completed”", "at": "2026-10-23T13:35:10.569Z", "withinLast7Days": false }, "origin": "automated" }, { "key": "trial:NCT07662213", "record": "Eluminate-2: A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus", "subtitle": "NCT07662213", "detail": "Conditions: Type 2 Diabetes Mellitus. Interventions: Elecoglipron; Semaglutide", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "AstraZeneca", "enrollment": "1200", "nctId": "NCT07662213" }, "jurisdiction": null, "date": "2026-10-22T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07662213", "url": "https://clinicaltrials.gov/study/NCT07662213", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-03T11:05:10.848Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-03T11:05:11.564Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07889648", "record": "ENI-SPIRE-2: A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications", "subtitle": "NCT07889648", "detail": "Conditions: Type 2 Diabetes Mellitus. Interventions: Enicepatide; Tirzepatide", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Hoffmann-La Roche", "enrollment": "948", "nctId": "NCT07889648" }, "jurisdiction": null, "date": "2026-10-22T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07889648", "url": "https://clinicaltrials.gov/study/NCT07889648", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-04T12:05:09.561Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-04T12:05:10.225Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07823452", "record": "GUT BOOST: Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With Obesity", "subtitle": "NCT07823452", "detail": "Conditions: Obesity & Overweight. Interventions: gut-brain axis (GLP-1)-activating food carbohydrate; starch-based placebo control (commercial maltodextrin)", "status": "Not yet recruiting", "fields": { "phase": "Phase 2", "sponsor": "Indiana University", "enrollment": "62", "nctId": "NCT07823452" }, "jurisdiction": null, "date": "2026-10-21T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07823452", "url": "https://clinicaltrials.gov/study/NCT07823452", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-26T07:35:06.557Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-26T07:35:07.270Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07107334", "record": "A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia", "subtitle": "NCT07107334", "detail": "Conditions: Endometrioid Endometrial Adenocarcinoma. Interventions: Glucagon-like peptide 1 receptor agonist", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "University of Florida", "enrollment": "20", "nctId": "NCT07107334" }, "jurisdiction": null, "date": "2026-10-21T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07107334", "url": "https://clinicaltrials.gov/study/NCT07107334", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:06.920Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:07.504Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07502508", "record": "Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy", "subtitle": "NCT07502508", "detail": "Conditions: Type 2 Diabetes. Interventions: icovamenib 100 mg; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "Biomea Fusion Inc.", "enrollment": "60", "nctId": "NCT07502508" }, "jurisdiction": null, "date": "2026-10-20T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07502508", "url": "https://clinicaltrials.gov/study/NCT07502508", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-29T06:35:09.275Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-29T06:35:09.869Z", "change": null, "origin": "automated" }, { "key": "trial:NCT04335656", "record": "Reducing Innate Inflammation in New Onset Type 1 Diabetes", "subtitle": "NCT04335656", "detail": "Conditions: Type 1 Diabetes; type1diabetes; Type 1 Diabetes Mellitus. Interventions: Lactiplantibacillus plantarum; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 2", "sponsor": "Medical College of Wisconsin", "enrollment": "51", "nctId": "NCT04335656" }, "jurisdiction": null, "date": "2026-10-20T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT04335656", "url": "https://clinicaltrials.gov/study/NCT04335656", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.068Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:05.363Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07884058", "record": "IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity", "subtitle": "NCT07884058", "detail": "Conditions: Obesity & Overweight. Interventions: IGOB131; Dextrin", "status": "Not yet recruiting", "fields": { "phase": "Phase 2", "sponsor": "University of Yaounde 1", "enrollment": "80", "nctId": "NCT07884058" }, "jurisdiction": null, "date": "2026-10-20T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07884058", "url": "https://clinicaltrials.gov/study/NCT07884058", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-26T07:35:06.557Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-26T07:35:07.417Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07654374", "record": "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)", "subtitle": "NCT07654374", "detail": "Conditions: Obesity; Overweight; Chronic Weight Management; Type2 Diabetes Mellitus. Interventions: aleniglipron; aleniglipron; aleniglipron; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics", "enrollment": "1100", "nctId": "NCT07654374" }, "jurisdiction": null, "date": "2026-10-20T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07654374", "url": "https://clinicaltrials.gov/study/NCT07654374", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-23T08:35:02.075Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-23T08:35:02.766Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07874828", "record": "PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study", "subtitle": "NCT07874828", "detail": "Conditions: Sarcoma,Soft Tissue. Interventions: Tirzepatide", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "M.D. Anderson Cancer Center", "enrollment": "30", "nctId": "NCT07874828" }, "jurisdiction": null, "date": "2026-10-20T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07874828", "url": "https://clinicaltrials.gov/study/NCT07874828", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-02T10:05:10.512Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-02T10:05:11.218Z", "change": { "note": "Status changed from “Not yet recruiting” to “Recruiting”", "at": "2026-10-20T17:35:01.959Z", "withinLast7Days": false }, "origin": "automated" }, { "key": "trial:NCT07879612", "record": "S-CUD: Semaglutide for the Treatment of Cannabis Use Disorder", "subtitle": "NCT07879612", "detail": "Conditions: Cannabis Use Disorder; Cue-reactivity. Interventions: semaglutide", "status": "Not yet recruiting", "fields": { "phase": "Phase 2", "sponsor": "Massachusetts General Hospital", "enrollment": "40", "nctId": "NCT07879612" }, "jurisdiction": null, "date": "2026-10-19T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07879612", "url": "https://clinicaltrials.gov/study/NCT07879612", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-28T05:35:10.706Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-28T05:35:11.710Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06976619", "record": "The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes", "subtitle": "NCT06976619", "detail": "Conditions: Type 1 Diabetes; Type 2 Diabetes. Interventions: Liraglutide Pen Injector; Saline Injections", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "Mayo Clinic", "enrollment": "60", "nctId": "NCT06976619" }, "jurisdiction": null, "date": "2026-10-19T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06976619", "url": "https://clinicaltrials.gov/study/NCT06976619", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:06.920Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:07.598Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06221969", "record": "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor", "subtitle": "NCT06221969", "detail": "Conditions: Type 2 Diabetes. Interventions: Cagrilintide; Semaglutide; Tirzepatide", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "1024", "nctId": "NCT06221969" }, "jurisdiction": null, "date": "2026-10-19T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06221969", "url": "https://clinicaltrials.gov/study/NCT06221969", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.068Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:05.405Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06534411", "record": "REIMAGINE 5: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both", "subtitle": "NCT06534411", "detail": "Conditions: Diabetes Mellitus, Type 2. Interventions: Cagrilintide; Semaglutide; Tirzepatide", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "1023", "nctId": "NCT06534411" }, "jurisdiction": null, "date": "2026-10-19T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06534411", "url": "https://clinicaltrials.gov/study/NCT06534411", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.068Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:05.531Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07282613", "record": "REIMAGINEYOUNG: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes", "subtitle": "NCT07282613", "detail": "Conditions: Diabetes Mellitus, Type 2. Interventions: CagriSema (Cagrilintide B and Semaglutide I); Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "80", "nctId": "NCT07282613" }, "jurisdiction": null, "date": "2026-10-19T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07282613", "url": "https://clinicaltrials.gov/study/NCT07282613", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.068Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:05.491Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06192108", "record": "ACHIEVE-2: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin", "subtitle": "NCT06192108", "detail": "Conditions: Type 2 Diabetes. Interventions: Orforglipron; Dapagliflozin", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "962", "nctId": "NCT06192108" }, "jurisdiction": null, "date": "2026-10-16T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06192108", "url": "https://clinicaltrials.gov/study/NCT06192108", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.987Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:06.319Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07868835", "record": "Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)", "subtitle": "NCT07868835", "detail": "Conditions: Weight Loss. Interventions: VK2735; Placebo comparator", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Viking Therapeutics, Inc.", "enrollment": "560", "nctId": "NCT07868835" }, "jurisdiction": null, "date": "2026-10-16T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07868835", "url": "https://clinicaltrials.gov/study/NCT07868835", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-21T12:05:09.902Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-21T12:05:10.458Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07868939", "record": "Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)", "subtitle": "NCT07868939", "detail": "Conditions: Weight Loss. Interventions: VK2735 Oral; Placebo Comparator", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Viking Therapeutics, Inc.", "enrollment": "560", "nctId": "NCT07868939" }, "jurisdiction": null, "date": "2026-10-16T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07868939", "url": "https://clinicaltrials.gov/study/NCT07868939", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-21T12:05:09.902Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-21T12:05:10.487Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07169942", "record": "Aleniglipron Phase 2 Body Composition Study", "subtitle": "NCT07169942", "detail": "Conditions: Obesity, Overweight, or Chronic Weight Management. Interventions: aleniglipron or placebo", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics", "enrollment": "71", "nctId": "NCT07169942" }, "jurisdiction": null, "date": "2026-10-14T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07169942", "url": "https://clinicaltrials.gov/study/NCT07169942", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-19T11:35:05.360Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-19T11:35:06.156Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06639464", "record": "SHORE: Semaglutide for Helping Opioid Recovery", "subtitle": "NCT06639464", "detail": "Conditions: Opioid Use Disorder. Interventions: Semaglutide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "Brigham and Women's Hospital", "enrollment": "46", "nctId": "NCT06639464" }, "jurisdiction": null, "date": "2026-10-13T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06639464", "url": "https://clinicaltrials.gov/study/NCT06639464", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-19T11:35:10.956Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-19T11:35:11.408Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07871799", "record": "ELITE: ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy Aging", "subtitle": "NCT07871799", "detail": "Conditions: Healthy Aging. Interventions: AgeBiotics AB-01; AgeBiotics AB-02; Metformin; semaglutide; empagliflozin", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Sheba Medical Center", "enrollment": "31", "nctId": "NCT07871799" }, "jurisdiction": null, "date": "2026-10-13T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07871799", "url": "https://clinicaltrials.gov/study/NCT07871799", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-19T11:35:10.956Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-19T11:35:11.577Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07064486", "record": "A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia", "subtitle": "NCT07064486", "detail": "Conditions: Type 2 Diabetes (T2DM). Interventions: BGM0504; BGM0504; Semaglutide", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "enrollment": "152", "nctId": "NCT07064486" }, "jurisdiction": null, "date": "2026-10-13T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07064486", "url": "https://clinicaltrials.gov/study/NCT07064486", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-20T11:35:13.682Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-20T11:35:14.511Z", "change": null, "origin": "automated" }, { "key": "trial:NCT04822181", "record": "ESSENCE: Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)", "subtitle": "NCT04822181", "detail": "Conditions: Non-alcoholic Steatohepatitis. Interventions: Semaglutide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "1205", "nctId": "NCT04822181" }, "jurisdiction": null, "date": "2026-10-13T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT04822181", "url": "https://clinicaltrials.gov/study/NCT04822181", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-20T11:35:13.682Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-20T11:35:14.426Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07743983", "record": "A Study of BGM0504 in Early T2DM With Obesity", "subtitle": "NCT07743983", "detail": "Conditions: Type 2 Diabetes (T2DM). Interventions: BGM0504; semaglutide", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "enrollment": "372", "nctId": "NCT07743983" }, "jurisdiction": null, "date": "2026-10-13T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07743983", "url": "https://clinicaltrials.gov/study/NCT07743983", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-20T11:35:13.682Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-20T11:35:14.466Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07553299", "record": "A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities", "subtitle": "NCT07553299", "detail": "Conditions: Obesity; Overweight; Weight Maintenance. Interventions: VRB-101; Placebo", "status": "Terminated", "fields": { "phase": "Phase 2", "sponsor": "Verdiva Bio Dev Limited", "enrollment": "8", "nctId": "NCT07553299" }, "jurisdiction": null, "date": "2026-10-13T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07553299", "url": "https://clinicaltrials.gov/study/NCT07553299", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-15T08:35:02.654Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-15T08:35:03.114Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06911203", "record": "A Study of BGM0504 in Participants With Obesity", "subtitle": "NCT06911203", "detail": "Conditions: Obesity. Interventions: BGM0504; Tirzepatide", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "enrollment": "96", "nctId": "NCT06911203" }, "jurisdiction": null, "date": "2026-10-13T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06911203", "url": "https://clinicaltrials.gov/study/NCT06911203", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-22T00:35:11.845Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-22T00:35:12.539Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07790861", "record": "ATTAIN-CN: A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems", "subtitle": "NCT07790861", "detail": "Conditions: Obesity; Overweight. Interventions: Orforglipron; Placebo", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "192", "nctId": "NCT07790861" }, "jurisdiction": null, "date": "2026-10-13T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07790861", "url": "https://clinicaltrials.gov/study/NCT07790861", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.987Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:06.358Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07215559", "record": "A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes", "subtitle": "NCT07215559", "detail": "Conditions: Obesity; Overweight; Diabetes Mellitus, Type 2. Interventions: Macupatide; Eloralintide; Macupatide Placebo; Eloralintide Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 2", "sponsor": "Eli Lilly and Company", "enrollment": "200", "nctId": "NCT07215559" }, "jurisdiction": null, "date": "2026-10-09T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07215559", "url": "https://clinicaltrials.gov/study/NCT07215559", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.068Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:05.622Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07265752", "record": "Tirzepatide for the Treatment of Cannabis Use Disorder", "subtitle": "NCT07265752", "detail": "Conditions: Cannabis Use Disorder. Interventions: Tirzepatide; Placebo", "status": "Not yet recruiting", "fields": { "phase": "Phase 2", "sponsor": "Brigham and Women's Hospital", "enrollment": "6", "nctId": "NCT07265752" }, "jurisdiction": null, "date": "2026-10-09T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07265752", "url": "https://clinicaltrials.gov/study/NCT07265752", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-20T11:35:12.715Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-20T11:35:13.564Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07165028", "record": "A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)", "subtitle": "NCT07165028", "detail": "Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease. Interventions: Tirzepatide; Retatrutide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "4500", "nctId": "NCT07165028" }, "jurisdiction": null, "date": "2026-10-08T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07165028", "url": "https://clinicaltrials.gov/study/NCT07165028", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:07.948Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:08.154Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06383390", "record": "The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)", "subtitle": "NCT06383390", "detail": "Conditions: Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD). Interventions: Retatrutide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "10000", "nctId": "NCT06383390" }, "jurisdiction": null, "date": "2026-10-08T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06383390", "url": "https://clinicaltrials.gov/study/NCT06383390", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:07.948Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:08.204Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07613307", "record": "ACHIEVE-RAM: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting", "subtitle": "NCT07613307", "detail": "Conditions: Diabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders; Metabolic Disorders; Nutritional and Metabolic Diseases; Endocr…. Interventions: Orforglipron", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "130", "nctId": "NCT07613307" }, "jurisdiction": null, "date": "2026-10-08T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07613307", "url": "https://clinicaltrials.gov/study/NCT07613307", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.987Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:06.397Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07153471", "record": "ATTAIN-OA PAIN: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee", "subtitle": "NCT07153471", "detail": "Conditions: Osteoarthritis. Interventions: Orforglipron; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "800", "nctId": "NCT07153471" }, "jurisdiction": null, "date": "2026-10-08T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07153471", "url": "https://clinicaltrials.gov/study/NCT07153471", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.987Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:06.435Z", "change": { "note": "Status changed from “Recruiting” to “Active, not recruiting”", "at": "2026-10-02T17:35:06.049Z", "withinLast7Days": false }, "origin": "automated" }, { "key": "trial:NCT07668388", "record": "A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes", "subtitle": "NCT07668388", "detail": "Conditions: Diabetes Mellitus, Type 2. Interventions: UBT251; UBT251 Placebo; Semaglutide; Semaglutide Placebo", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "Novo Nordisk A/S", "enrollment": "300", "nctId": "NCT07668388" }, "jurisdiction": null, "date": "2026-10-07T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07668388", "url": "https://clinicaltrials.gov/study/NCT07668388", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-15T08:05:13.817Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-15T08:05:14.682Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06143956", "record": "A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight", "subtitle": "NCT06143956", "detail": "Conditions: Obesity; Overweight. Interventions: LY3305677; LY3841136; Tirzepatide; LY3549492; LY3532226; Placebo; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "Eli Lilly and Company", "enrollment": "1481", "nctId": "NCT06143956" }, "jurisdiction": null, "date": "2026-10-07T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06143956", "url": "https://clinicaltrials.gov/study/NCT06143956", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-16T09:05:09.066Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-16T09:05:09.678Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07220759", "record": "RENEW 2: Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide", "subtitle": "NCT07220759", "detail": "Conditions: Overweight; Obesity; Type 2 Diabetes. Interventions: Cagrilintide; Placebo (matched to Cagrilintide)", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "330", "nctId": "NCT07220759" }, "jurisdiction": null, "date": "2026-10-07T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07220759", "url": "https://clinicaltrials.gov/study/NCT07220759", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.068Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:05.659Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05726227", "record": "STEP Young: A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight", "subtitle": "NCT05726227", "detail": "Conditions: Obesity. Interventions: Semaglutide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "212", "nctId": "NCT05726227" }, "jurisdiction": null, "date": "2026-10-07T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05726227", "url": "https://clinicaltrials.gov/study/NCT05726227", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-15T08:05:13.817Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-15T08:05:14.853Z", "change": null, "origin": "automated" }, { "key": "trial:NCT03811561", "record": "FOCUS: A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes", "subtitle": "NCT03811561", "detail": "Conditions: Diabetes Mellitus, Type 2. Interventions: Semaglutide; Placebo (semaglutide)", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "1500", "nctId": "NCT03811561" }, "jurisdiction": null, "date": "2026-10-07T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT03811561", "url": "https://clinicaltrials.gov/study/NCT03811561", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-15T08:05:13.817Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-15T08:05:14.802Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06896981", "record": "Semaglutide in Women With Polycystic Ovary Syndrome and Obesity", "subtitle": "NCT06896981", "detail": "Conditions: Polycystic Ovary Syndrome (PCOS) Women; Obesity. Interventions: Metformin with Semaglutide", "status": "Completed", "fields": { "phase": "Phase 2 / Phase 3", "sponsor": "Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh", "enrollment": "31", "nctId": "NCT06896981" }, "jurisdiction": null, "date": "2026-10-07T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06896981", "url": "https://clinicaltrials.gov/study/NCT06896981", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-14T07:05:14.001Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-14T07:05:14.586Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07284979", "record": "KaiNETIC-3: Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes", "subtitle": "NCT07284979", "detail": "Conditions: Obesity. Interventions: Ribupatide; Semaglutide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Kailera", "enrollment": "1270", "nctId": "NCT07284979" }, "jurisdiction": null, "date": "2026-10-06T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07284979", "url": "https://clinicaltrials.gov/study/NCT07284979", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-14T07:05:14.001Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-14T07:05:14.646Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07284875", "record": "KaiNETIC-1: Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes", "subtitle": "NCT07284875", "detail": "Conditions: Obesity; Overweight. Interventions: Ribupatide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Kailera", "enrollment": "2530", "nctId": "NCT07284875" }, "jurisdiction": null, "date": "2026-10-06T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07284875", "url": "https://clinicaltrials.gov/study/NCT07284875", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-09T02:35:09.639Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-09T02:35:10.431Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07284901", "record": "KaiNETIC-2: Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes", "subtitle": "NCT07284901", "detail": "Conditions: Obesity With Diabetes; Overweight With Diabetes. Interventions: Ribupatide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Kailera", "enrollment": "1270", "nctId": "NCT07284901" }, "jurisdiction": null, "date": "2026-10-06T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07284901", "url": "https://clinicaltrials.gov/study/NCT07284901", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-09T02:35:09.639Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-09T02:35:10.632Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06058585", "record": "CAPTIVATE: The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect", "subtitle": "NCT06058585", "detail": "Conditions: Chronic Kidney Diseases. Interventions: Finerenone; Placebo Finerenone; Semaglutide; Placebo semaglutide", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "The George Institute", "enrollment": "2000", "nctId": "NCT06058585" }, "jurisdiction": null, "date": "2026-10-05T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06058585", "url": "https://clinicaltrials.gov/study/NCT06058585", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-08T02:35:10.380Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-08T02:35:11.426Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06050577", "record": "The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial", "subtitle": "NCT06050577", "detail": "Conditions: Type 2 Diabetes; Osteopenia. Interventions: oral Semaglutide/Rybelsus; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 2", "sponsor": "Odense University Hospital", "enrollment": "64", "nctId": "NCT06050577" }, "jurisdiction": null, "date": "2026-10-05T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06050577", "url": "https://clinicaltrials.gov/study/NCT06050577", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-13T07:05:04.540Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-13T07:05:05.204Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06073184", "record": "WE-FiERCE: Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium", "subtitle": "NCT06073184", "detail": "Conditions: Endometrial Cancer; Atypical Hyperplasia; Fertility Perservation. Interventions: Wegovy; Mirena", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "GynOncTrials", "enrollment": "71", "nctId": "NCT06073184" }, "jurisdiction": null, "date": "2026-10-05T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06073184", "url": "https://clinicaltrials.gov/study/NCT06073184", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-09T03:35:05.863Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-09T03:35:06.728Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06726577", "record": "TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis", "subtitle": "NCT06726577", "detail": "Conditions: Amyotrophic Lateral Sclerosis. Interventions: TP04HN106; Saline", "status": "Recruiting", "fields": { "phase": "Phase 1 / Phase 2", "sponsor": "Talengen Institute of Life Sciences, Shenzhen, P.R. China.", "enrollment": "60", "nctId": "NCT06726577" }, "jurisdiction": null, "date": "2026-10-02T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06726577", "url": "https://clinicaltrials.gov/study/NCT06726577", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:06.920Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:07.817Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07249554", "record": "Combination Therapy for Alcohol Use Disorder", "subtitle": "NCT07249554", "detail": "Conditions: Alcohol Use Disorder. Interventions: Placebo; Glucagon-Like Peptide-1 Agonist (GLP-1); Naltrexone (oral tablets)", "status": "Not yet recruiting", "fields": { "phase": "Phase 2", "sponsor": "Johns Hopkins University", "enrollment": "45", "nctId": "NCT07249554" }, "jurisdiction": null, "date": "2026-10-01T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07249554", "url": "https://clinicaltrials.gov/study/NCT07249554", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-06T00:35:10.233Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-06T00:35:10.759Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07820358", "record": "SWIFT: Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer", "subtitle": "NCT07820358", "detail": "Conditions: Endometrial Atypical Hyperplasia; Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; Endometrial Cancer Stage I; Endo…. Interventions: Semaglutide (Wegovy) weekly injection; LNG-IUD (Progestin); Structured Weight Loss Program", "status": "Not yet recruiting", "fields": { "phase": "Phase 2", "sponsor": "The Methodist Hospital Research Institute", "enrollment": "48", "nctId": "NCT07820358" }, "jurisdiction": null, "date": "2026-10-01T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07820358", "url": "https://clinicaltrials.gov/study/NCT07820358", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-05T12:05:14.174Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-05T12:05:14.381Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06109311", "record": "ACHIEVE-5: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor", "subtitle": "NCT06109311", "detail": "Conditions: Type 2 Diabetes. Interventions: Orforglipron; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "546", "nctId": "NCT06109311" }, "jurisdiction": null, "date": "2026-10-01T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06109311", "url": "https://clinicaltrials.gov/study/NCT06109311", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.987Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:06.490Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05254314", "record": "GATA-3: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)", "subtitle": "NCT05254314", "detail": "Conditions: Asthma. Interventions: Semaglutide Pen Injector 2.4mg weekly; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 2", "sponsor": "Vanderbilt University Medical Center", "enrollment": "100", "nctId": "NCT05254314" }, "jurisdiction": null, "date": "2026-10-01T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05254314", "url": "https://clinicaltrials.gov/study/NCT05254314", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-05T12:05:14.174Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-05T12:05:14.531Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06323174", "record": "REIMAGINE 1: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise", "subtitle": "NCT06323174", "detail": "Conditions: Type 2 Diabetes. Interventions: Cagrilintide; Semaglutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "189", "nctId": "NCT06323174" }, "jurisdiction": null, "date": "2026-09-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06323174", "url": "https://clinicaltrials.gov/study/NCT06323174", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.068Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:05.734Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07817251", "record": "Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema", "subtitle": "NCT07817251", "detail": "Conditions: Diabetes Mellitus, Type 2. Interventions: CagriSema", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "210", "nctId": "NCT07817251" }, "jurisdiction": null, "date": "2026-09-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07817251", "url": "https://clinicaltrials.gov/study/NCT07817251", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.068Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:05.696Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07011667", "record": "A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term", "subtitle": "NCT07011667", "detail": "Conditions: Obesity. Interventions: CagriSema (Cagrilintide B and Semaglutide I); Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "609", "nctId": "NCT07011667" }, "jurisdiction": null, "date": "2026-09-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07011667", "url": "https://clinicaltrials.gov/study/NCT07011667", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.068Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:05.816Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07564414", "record": "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight", "subtitle": "NCT07564414", "detail": "Conditions: Obesity; Type 2 Diabetes. Interventions: Cagrisema; Semaglutide", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "2500", "nctId": "NCT07564414" }, "jurisdiction": null, "date": "2026-09-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07564414", "url": "https://clinicaltrials.gov/study/NCT07564414", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.068Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:05.855Z", "change": null, "origin": "automated" }, { "key": "trial:NCT03449251", "record": "DEFINE: A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin", "subtitle": "NCT03449251", "detail": "Conditions: Cardiovascular Diseases; Type 2 Diabetes Mellitus. Interventions: Apelin; Relaxin; Normal saline; Verapamil; LN Monomethyl arginine", "status": "Active, not recruiting", "fields": { "phase": "Phase 2", "sponsor": "Cambridge University Hospitals NHS Foundation Trust", "enrollment": "170", "nctId": "NCT03449251" }, "jurisdiction": null, "date": "2026-09-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT03449251", "url": "https://clinicaltrials.gov/study/NCT03449251", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-05T12:05:07.316Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-05T12:05:08.179Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07253285", "record": "A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight", "subtitle": "NCT07253285", "detail": "Conditions: Overweight; Obesity. Interventions: Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "460", "nctId": "NCT07253285" }, "jurisdiction": null, "date": "2026-09-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07253285", "url": "https://clinicaltrials.gov/study/NCT07253285", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.068Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:05.777Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05567796", "record": "REDEFINE 1: A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight", "subtitle": "NCT05567796", "detail": "Conditions: Obesity. Interventions: Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "3400", "nctId": "NCT05567796" }, "jurisdiction": null, "date": "2026-09-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05567796", "url": "https://clinicaltrials.gov/study/NCT05567796", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-13T06:35:06.964Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-13T06:35:07.903Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06771115", "record": "Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity", "subtitle": "NCT06771115", "detail": "Conditions: Obesity. Interventions: Placebo; VTX3232 30 mg; Placebo in combination with semaglutide; VTX3232 30 mg in combination with semaglutide", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Zomagen Biosciences Ltd.", "enrollment": "175", "nctId": "NCT06771115" }, "jurisdiction": null, "date": "2026-09-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06771115", "url": "https://clinicaltrials.gov/study/NCT06771115", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:20.487Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:21.027Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07527910", "record": "A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD", "subtitle": "NCT07527910", "detail": "Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Interventions: ALN-PNP; Tirzepatide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 2", "sponsor": "Regeneron Pharmaceuticals", "enrollment": "204", "nctId": "NCT07527910" }, "jurisdiction": null, "date": "2026-09-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07527910", "url": "https://clinicaltrials.gov/study/NCT07527910", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-07T01:35:11.195Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-07T01:35:11.865Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05305794", "record": "TOLEDDO: Effect of Weekly GLP1 Agonist Treatment in \"Double Diabetes\"", "subtitle": "NCT05305794", "detail": "Conditions: Double Diabetes. Interventions: Insulin + semaglutide treatment; Usual insulin treatment; Biological check-up", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Centre Hospitalier Universitaire Dijon", "enrollment": "76", "nctId": "NCT05305794" }, "jurisdiction": null, "date": "2026-09-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05305794", "url": "https://clinicaltrials.gov/study/NCT05305794", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-12T05:35:12.563Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-12T05:35:13.156Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06603571", "record": "A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes", "subtitle": "NCT06603571", "detail": "Conditions: Obesity; Overweight. Interventions: LY3841136; Tirzepatide; Placebo", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Eli Lilly and Company", "enrollment": "367", "nctId": "NCT06603571" }, "jurisdiction": null, "date": "2026-09-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06603571", "url": "https://clinicaltrials.gov/study/NCT06603571", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-07T01:35:11.195Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-07T01:35:11.905Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07724340", "record": "A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity", "subtitle": "NCT07724340", "detail": "Conditions: Adults With Overweight/Obesity and Type 2 Diabetes. Interventions: AT673 low dose; AT673 high dose; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 2", "sponsor": "Antag Therapeutics", "enrollment": "150", "nctId": "NCT07724340" }, "jurisdiction": null, "date": "2026-09-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07724340", "url": "https://clinicaltrials.gov/study/NCT07724340", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-01T09:05:20.487Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-01T09:05:20.975Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07845994", "record": "SEMAFORCRANIO: SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years", "subtitle": "NCT07845994", "detail": "Conditions: Craniopharyngioma, Child. Interventions: Semaglutide (Wegovy) weekly injection; Placebo weekly Injection", "status": "Not yet recruiting", "fields": { "phase": "Phase 3", "sponsor": "University Hospital, Angers", "enrollment": "50", "nctId": "NCT07845994" }, "jurisdiction": null, "date": "2026-09-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07845994", "url": "https://clinicaltrials.gov/study/NCT07845994", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-02T10:05:15.575Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-02T10:05:16.635Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06745128", "record": "Tirzepatide for Obesity and Meth Use Disorder", "subtitle": "NCT06745128", "detail": "Conditions: Obesity; Methamphetamine Use Disorder. Interventions: Tirzepatide", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "University of Texas Southwestern Medical Center", "enrollment": "35", "nctId": "NCT06745128" }, "jurisdiction": null, "date": "2026-09-28T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06745128", "url": "https://clinicaltrials.gov/study/NCT06745128", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-06T00:35:09.542Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-06T00:35:10.130Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06260722", "record": "Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)", "subtitle": "NCT06260722", "detail": "Conditions: Diabetes Mellitus, Type 2. Interventions: Retatrutide; Semaglutide", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "1250", "nctId": "NCT06260722" }, "jurisdiction": null, "date": "2026-09-28T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06260722", "url": "https://clinicaltrials.gov/study/NCT06260722", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:07.948Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:08.284Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07078838", "record": "Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer", "subtitle": "NCT07078838", "detail": "Conditions: Endometrial Cancer; Endometrial Intraepithelial Neoplasia; Grade 1 Endometrial Endometrioid Carcinoma. Interventions: Tirzepatide", "status": "Not yet recruiting", "fields": { "phase": "Phase 2", "sponsor": "UNC Lineberger Comprehensive Cancer Center", "enrollment": "40", "nctId": "NCT07078838" }, "jurisdiction": null, "date": "2026-09-28T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07078838", "url": "https://clinicaltrials.gov/study/NCT07078838", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-05T12:05:12.999Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-05T12:05:13.658Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07035093", "record": "TRIUMPH-7: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain", "subtitle": "NCT07035093", "detail": "Conditions: Obesity; Overweight; Chronic Low Back Pain (CLBP). Interventions: Retatrutide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "586", "nctId": "NCT07035093" }, "jurisdiction": null, "date": "2026-09-25T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07035093", "url": "https://clinicaltrials.gov/study/NCT07035093", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:07.948Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:08.321Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06439277", "record": "A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)", "subtitle": "NCT06439277", "detail": "Conditions: Obesity; Weight Gain. Interventions: Tirzepatide; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "300", "nctId": "NCT06439277" }, "jurisdiction": null, "date": "2026-09-24T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06439277", "url": "https://clinicaltrials.gov/study/NCT06439277", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-02T10:05:14.219Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-02T10:05:15.361Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06131372", "record": "A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo", "subtitle": "NCT06131372", "detail": "Conditions: Chronic Kidney Disease; Type 2 Diabetes; Obesity. Interventions: Cagrilintide; Semaglutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Novo Nordisk A/S", "enrollment": "626", "nctId": "NCT06131372" }, "jurisdiction": null, "date": "2026-09-24T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06131372", "url": "https://clinicaltrials.gov/study/NCT06131372", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-04T12:05:06.296Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-04T12:05:06.984Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06045221", "record": "ACHIEVE-3: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin", "subtitle": "NCT06045221", "detail": "Conditions: Type 2 Diabetes. Interventions: Orforglipron; Semaglutide", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "1698", "nctId": "NCT06045221" }, "jurisdiction": null, "date": "2026-09-15T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06045221", "url": "https://clinicaltrials.gov/study/NCT06045221", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.987Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:06.530Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06649045", "record": "ATTAIN-OSA: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight", "subtitle": "NCT06649045", "detail": "Conditions: OSA; Overweight or Obesity. Interventions: Orforglipron; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "712", "nctId": "NCT06649045" }, "jurisdiction": null, "date": "2026-09-14T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06649045", "url": "https://clinicaltrials.gov/study/NCT06649045", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.987Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:06.587Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07815678", "record": "First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671", "subtitle": "NCT07815678", "detail": "Conditions: Obesity. Interventions: ACCG-2671; Placebo", "status": "Recruiting", "fields": { "phase": "Phase 1 / Phase 2", "sponsor": "Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics", "enrollment": "164", "nctId": "NCT07815678" }, "jurisdiction": null, "date": "2026-09-14T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07815678", "url": "https://clinicaltrials.gov/study/NCT07815678", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-19T11:35:06.335Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-19T11:35:07.204Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06797869", "record": "A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy", "subtitle": "NCT06797869", "detail": "Conditions: Diabetes Mellitus, Type 2; Diabetic Peripheral Neuropathy. Interventions: CagriSema (Cagrilintide B and Semaglutide I); Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Novo Nordisk A/S", "enrollment": "142", "nctId": "NCT06797869" }, "jurisdiction": null, "date": "2026-09-10T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06797869", "url": "https://clinicaltrials.gov/study/NCT06797869", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-19T11:35:06.335Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-19T11:35:07.237Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06323161", "record": "REIMAGINE 3: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin", "subtitle": "NCT06323161", "detail": "Conditions: Type 2 Diabetes. Interventions: Cagrilintide; Semaglutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "274", "nctId": "NCT06323161" }, "jurisdiction": null, "date": "2026-09-09T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06323161", "url": "https://clinicaltrials.gov/study/NCT06323161", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-08T02:35:03.830Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-08T02:35:04.846Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06926842", "record": "Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)", "subtitle": "NCT06926842", "detail": "Conditions: Overweight; Type 2 Diabetes; Obesity. Interventions: Petrelintide; Placebo", "status": "Completed", "fields": { "phase": "Phase 2", "sponsor": "Zealand Pharma", "enrollment": "221", "nctId": "NCT06926842" }, "jurisdiction": null, "date": "2026-09-09T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06926842", "url": "https://clinicaltrials.gov/study/NCT06926842", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-06T00:35:06.752Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-06T00:35:07.306Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05872620", "record": "ATTAIN-2: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes", "subtitle": "NCT05872620", "detail": "Conditions: Obesity; Overweight; Type 2 Diabetes. Interventions: Orforglipron; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "1613", "nctId": "NCT05872620" }, "jurisdiction": null, "date": "2026-09-04T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05872620", "url": "https://clinicaltrials.gov/study/NCT05872620", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.987Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:06.670Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05971940", "record": "ACHIEVE-1: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone", "subtitle": "NCT05971940", "detail": "Conditions: Type 2 Diabetes. Interventions: Orforglipron; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "559", "nctId": "NCT05971940" }, "jurisdiction": null, "date": "2026-09-03T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05971940", "url": "https://clinicaltrials.gov/study/NCT05971940", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.987Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:06.710Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05965908", "record": "Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome", "subtitle": "NCT05965908", "detail": "Conditions: Polycystic Ovary. Interventions: liraglutide; Metformin", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Beni-Suef University", "enrollment": "183", "nctId": "NCT05965908" }, "jurisdiction": null, "date": "2026-08-25T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05965908", "url": "https://clinicaltrials.gov/study/NCT05965908", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-02T10:05:08.858Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-02T10:05:09.551Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05929066", "record": "TRIUMPH-1: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight", "subtitle": "NCT05929066", "detail": "Conditions: Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea. Interventions: Retatrutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "2335", "nctId": "NCT05929066" }, "jurisdiction": null, "date": "2026-08-21T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05929066", "url": "https://clinicaltrials.gov/study/NCT05929066", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:07.948Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:08.356Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05869903", "record": "ATTAIN-1: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities", "subtitle": "NCT05869903", "detail": "Conditions: Obesity; Overweight; Overweight or Obesity. Interventions: Orforglipron; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "3127", "nctId": "NCT05869903" }, "jurisdiction": null, "date": "2026-08-14T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05869903", "url": "https://clinicaltrials.gov/study/NCT05869903", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:05.987Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:06.801Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06993792", "record": "A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes", "subtitle": "NCT06993792", "detail": "Conditions: Obesity; Overweight; Type 2 Diabetes. Interventions: Orforglipron; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "1400", "nctId": "NCT06993792" }, "jurisdiction": null, "date": "2026-07-31T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06993792", "url": "https://clinicaltrials.gov/study/NCT06993792", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-21T12:05:11.506Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-21T12:05:12.143Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05929079", "record": "TRIUMPH-2: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight", "subtitle": "NCT05929079", "detail": "Conditions: Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea. Interventions: Retatrutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "1152", "nctId": "NCT05929079" }, "jurisdiction": null, "date": "2026-07-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05929079", "url": "https://clinicaltrials.gov/study/NCT05929079", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:07.948Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:08.430Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05882045", "record": "TRIUMPH-3: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease", "subtitle": "NCT05882045", "detail": "Conditions: Obesity; Cardiovascular Diseases. Interventions: Retatrutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "1946", "nctId": "NCT05882045" }, "jurisdiction": null, "date": "2026-07-30T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05882045", "url": "https://clinicaltrials.gov/study/NCT05882045", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:07.948Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:08.467Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06972459", "record": "A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity", "subtitle": "NCT06972459", "detail": "Conditions: Obesity; Overweight. Interventions: Orforglipron; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "800", "nctId": "NCT06972459" }, "jurisdiction": null, "date": "2026-07-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06972459", "url": "https://clinicaltrials.gov/study/NCT06972459", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-16T09:05:06.830Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-16T09:05:07.433Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06662383", "record": "TRIUMPH-5: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity", "subtitle": "NCT06662383", "detail": "Conditions: Obesity. Interventions: Retatrutide; Tirzepatide", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "800", "nctId": "NCT06662383" }, "jurisdiction": null, "date": "2026-07-20T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06662383", "url": "https://clinicaltrials.gov/study/NCT06662383", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:07.948Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:08.504Z", "change": null, "origin": "automated" }, { "key": "trial:NCT04775082", "record": "SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity", "subtitle": "NCT04775082", "detail": "Conditions: Obesity. Interventions: Liraglutide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Novo Nordisk A/S", "enrollment": "78", "nctId": "NCT04775082" }, "jurisdiction": null, "date": "2026-07-09T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT04775082", "url": "https://clinicaltrials.gov/study/NCT04775082", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-19T11:35:08.233Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-19T11:35:09.109Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07357415", "record": "TRIUMPH-9: A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight", "subtitle": "NCT07357415", "detail": "Conditions: Obesity; Overweight. Interventions: Retatrutide", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "600", "nctId": "NCT07357415" }, "jurisdiction": null, "date": "2026-06-09T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07357415", "url": "https://clinicaltrials.gov/study/NCT07357415", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:07.948Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:08.585Z", "change": null, "origin": "automated" }, { "key": "trial:NCT07613437", "record": "GLICH: GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial", "subtitle": "NCT07613437", "detail": "Conditions: Intracerebral Hemorrhage. Interventions: Semaglutide, 0.5 mg/mL", "status": "Not yet recruiting", "fields": { "phase": "Phase 2", "sponsor": "Chinese University of Hong Kong", "enrollment": "200", "nctId": "NCT07613437" }, "jurisdiction": null, "date": "2026-05-29T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT07613437", "url": "https://clinicaltrials.gov/study/NCT07613437", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-10-05T12:05:10.697Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-10-05T12:05:11.689Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06354660", "record": "Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)", "subtitle": "NCT06354660", "detail": "Conditions: Diabetes Type 2. Interventions: Retatrutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "537", "nctId": "NCT06354660" }, "jurisdiction": null, "date": "2026-03-05T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06354660", "url": "https://clinicaltrials.gov/study/NCT06354660", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:07.948Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:08.642Z", "change": null, "origin": "automated" }, { "key": "trial:NCT06859268", "record": "TRIUMPH-6: A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity", "subtitle": "NCT06859268", "detail": "Conditions: Obesity. Interventions: Retatrutide; Placebo", "status": "Active, not recruiting", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "643", "nctId": "NCT06859268" }, "jurisdiction": null, "date": "2026-03-03T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT06859268", "url": "https://clinicaltrials.gov/study/NCT06859268", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:07.948Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:08.685Z", "change": null, "origin": "automated" }, { "key": "trial:NCT05931367", "record": "TRIUMPH-4: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee", "subtitle": "NCT05931367", "detail": "Conditions: Obesity; Overweight; Osteo Arthritis Knee. Interventions: Retatrutide; Placebo", "status": "Completed", "fields": { "phase": "Phase 3", "sponsor": "Eli Lilly and Company", "enrollment": "445", "nctId": "NCT05931367" }, "jurisdiction": null, "date": "2026-01-21T00:00:00.000Z", "dateType": "Last update posted", "source": { "title": "ClinicalTrials.gov record NCT05931367", "url": "https://clinicaltrials.gov/study/NCT05931367", "publisher": "ClinicalTrials.gov (U.S. National Library of Medicine)", "type": "Primary source" }, "lastChecked": "2026-11-15T08:35:07.948Z", "checkedBy": "system", "nphlaUpdatedAt": "2026-11-15T08:35:08.740Z", "change": null, "origin": "automated" } ] }